•  
  •  
 

Corresponding Author

Mohamed Yehia Shehata Kotb Ahmed Dagher

Document Type

Original Article

Abstract

Background: Ocular consequences of diabetes include cataracts and diabetic macular edema, the latter of which is the most common cause of visual impairment in diabetic individuals.

Aim and objectives: To compare the efficacy and safety of phacoemulsification with injectable bevacizumab for diabetic macular edema to that of a staged procedure that begins with injectable bevacizumab and then proceeds to phacoemulsification using optical coherence tomography.

Patients and methods: A prospective interventional research was carried out at Al-Azhar University Hospitals on 40 cataractous eyes with diabetic macular edema. All patients were separated into 2 groups: Group A, in which twenty eyes were managed by intravitreal injection of Bevacizumab 0.05ml (1.25mg) then underwent phacoemulsification after 2 weeks, and Group B, in which 20 eyes were managed by combined phacoemulsification & intravitreal injection of Bevacizumab 0.05ml (1.25mg) in the same session. After surgery, patients were monitored for 1 month, 2 months, and 3 months to record their CMT and best corrected visual acuity.

Results: No statistically significant difference had been found among groups considering baseline CMT before operation, one and 2 months postoperative; however, the mean of CMT decreased significantly after 1 and 2 months in both staged and combined groups. No significant difference was found among both groups considering baseline BCVA before operation. The mean of BCVA increased significantly after one and two months in both groups.

Conclusion: No significant difference among groups considering baseline CMT before operation, 1 and 2 months postoperative.

Keywords

Diabetic; macular edema; Cataract; Bevacizumab; phacoemulsification

Subject Area

Ophthalmology

Download

Share

COinS